Jacobien R. Hilberink

Jacobien R. Hilberink

Auto-generated profile, based on publicly available information

Jacobien R. Hilberink

Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Science Advances
Verified
Journal Article
Open access
IWIsabel Weinhäuser
Isabel Weinhäuser
DPDiego A Pereira-Martins
Diego A Pereira-Martins
LALuciana Yamamoto de Almeida
Luciana Yamamoto de Almeida
JHJacobien R. Hilberink
Jacobien R. Hilberink
DSDouglas Silveira
Douglas Silveira
JSJan Jacob Schuringa
Jan Jacob Schuringa
It is increasingly becoming clear that cancers are a symbiosis of diverse cell types and tumor clones. Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune compartment in the bone marrow of patients with acute myeloid leukemia (AML) reveal a shift toward a tumor-supportive M2-polarized macrophage landscape with an altered transcriptional program, with enhanced fatty acid oxidation and NAD + generation. Functionally, these AML-associated macrophages display decreased phagocytic activity and intra–bone marrow coinjection of M2 macrophages together with leukemic blasts strongly enhances in vivo transformation potential. A 2-day in vitro exposure to M2 macrophages results in the accumulation of CALR low leukemic blast cells, which are now protected against phagocytosis. Moreover, M2-exposed “trained” leukemic blasts display increased mitochondrial metabolism, in part mediated via mitochondrial transfer. Our study provides insight into the mechanisms by which the immune landscape contributes to aggressive leukemia development and provides alternatives for targeting strategies aimed at the tumor microenvironment.

18 May 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
SHSe Young Han
Se Young Han
KMKrzysztof Mrózek
Krzysztof Mrózek
JVJenna Voutsinas
Jenna Voutsinas
QWQian Wu
Qian Wu
EMElizabeth A. Morgan
Elizabeth A. Morgan
CYCecilia C. S. Yeung
Cecilia C. S. Yeung
Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21).

1 May 2019 in Leukemia Research
Verified
Journal Article
Open access
JHJacobien Hilberink
Jacobien Hilberink
CHCarin Hazenberg
Carin Hazenberg
EBEva van Den Berg
Eva van Den Berg
AMAndré Mulder
André Mulder
JSJan Jacob Schuringa
Jan Jacob Schuringa
GHGerwin Huls
Gerwin Huls
Therapeutic decision making is often challenging in older AML patients. We collected retrospective data of 355 consecutive AML patients (≥60 years) who were treated with intensive chemotherapy (IC) (n = 155), hypomethylating agents (HMA) (n = 83), or best supportive care (BSC) (n = 117) between 2002 and 2017. Overall survival (OS) and response rates after therapy were analyzed. Multivariate Cox regression was performed to analyze the impact of different treatment strategies on survival. The median OS was not significantly different between patients treated with IC or HMA (14.9 vs 10.9 months; HR = 1.32, p = 0.076)), despite a difference in complete remission rate (59% after IC vs 35% after HMA). Patients who received a allogeneic hematopoietic cell transplantation (allo HCT) after treatment with IC or HMA had a significant survival benefit compared to patient who didn't proceed to allo HCT (median OS 65 vs 8 months, respectively, p < 0.001). The type of induction therapy (i.e. IC or HMA) did not impact on survival after allo HCT (48 vs 65 months, respectively, p = 0.440). In conclusion, consolidation with an allo HCT provides a significant benefit for older AML patients independent of upfront treatment with IC or HMA. Our data suggest that more older patients should be considered for an allo HCT.

1 March 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JHJacobien R. Hilberink
Jacobien R. Hilberink
LMLinde M. Morsink
Linde M. Morsink
WVWalter J.F.M van der Velden
Walter J.F.M van der Velden
AMAndré B. Mulder
André B. Mulder
CHCarin L.E Hazenberg
Carin L.E Hazenberg
GHGerwin Huls
Gerwin Huls
The predictive value of measurable residual disease (MRD) for survival in acute myeloid leukemia (AML) has been firmly established in younger patients treated with intensive chemotherapy. The value of MRD after treatment with decitabine in older patients is unknown. This retrospective analysis included patients ≥60 years of age with AML who received an allogeneic hematopoietic cell transplantation (alloHCT) after treatment with decitabine or intensive chemotherapy. Of the 133 consecutively transplanted patients, 109 had available pretransplantation MRD analyses (by flowcytometry [threshold 0.1%]). Forty patients received decitabine treatment (10-day schedule), and 69 patients received intensive chemotherapy (7 + 3 regimen). Patients who received decitabine were older (median 67 versus 64 years) and more often had MRD (70% versus 38%). OS after alloHCT was comparable in both groups. In the chemotherapy group, MRD-positive patients had a significantly higher relapse probability (subdistribution hazard ratio [sHR] 4.81; P= .0031) and risk of death (HR 2.8; P= .02) compared to MRD-negative patients. In the decitabine group there was no significant association between the presence of MRD and relapse (sHR 0.85; P= .83) or death (HR 0.72; P= .60). Pretransplantation MRD in patients receiving decitabine treatment does not have similar predictive value for relapse or survival in older AML patients receiving an alloHCT, compared to patients receiving intensive chemotherapy.

6 April 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MCMarjan Cruijsen
Marjan Cruijsen
JHJacobien R. Hilberink
Jacobien R. Hilberink
WVWalter J. F. M. van der Velden
Walter J. F. M. van der Velden
JJJoop H. Jansen
Joop H. Jansen
BBBrigitte Bär
Brigitte Bär
GHGerwin Huls
Gerwin Huls

19 June 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JHJacobien R. Hilberink
Jacobien R. Hilberink
IZIsabelle A. van Zeventer
Isabelle A. van Zeventer
DCDana A. Chitu
Dana A. Chitu
Thomas PabstThomas Pabst
Thomas Pabst
SKSaskia Klein
Saskia Klein
S(Swiss Group for Clinical Cancer Research (SAKK)
Swiss Group for Clinical Cancer Research (SAKK)
Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery < 9 and 17% ADL index < 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.